Deoxynojirimycin (19130-96-2) inhibits α-glucosidase I and II1,2. Inhibits human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step3. May be used to produce an affinity ligand for purifying glucosidase 14. Deoxynojirimycin was used to inhibit ER glucosidases I and II allowing for the discovery of a second mechanism for deglucosylation of N-linked oligosaccharides in PhaR1.7, a mouse lymphoma cell line5.
1) Fuhrmann et al. (1985), Inhibitors of oligosaccharide processing; Biochim. Biophys, Acta, 825 95
2) Hughs and Rudge (1994), Deoxynojirimycin: synthesis and biological activity; Nat. Prod. Rep., 11 135
3) Papandreou et al. (2002), The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step; Mol. Pharmacol., 61 186
4) Hettkamp et al. (1984), Purification by affinity chromatography of glucosidase I, an endoplasmic reticulum hydrolase involved in the processing of asparagine-linked oligosaccharides; Eur. J. Biochem., 142 85
5) Suh et al. (1992), Identification of a novel mechanism for the removal of glucose residues from high mannose-type oligosaccharides; J. Biol. Chem., 267 21671